Fractyl Health announced that the primary six-month efficacy data of its pivotal REMAIN-1 study is expected to be available in early Q4 2026.

老虎证券2026/07/15 10:17

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Faraday Future adds government procurement veteran Steven Newton as senior strategic advisor

Reuters•2026/09/13 23:00

JPMorgan: Tesla (TSLA.US) Robotaxi revenue may reach $320 billions by 2035, with nearly 98% coming from its own fleet

JPMorgan analyst Rajat Gupta released a research report last week, estimating that by 2035, Tesla's Robotaxi revenue will reach approximately $320 billion, with nearly $314 billion coming from Tesla's own and operated fleet, rather than from the owner-operated "Tesla Network."

智通财经•2026/09/13 22:56

FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans

Reuters•2026/09/13 22:32

Charles Hoskinson Says AI Has Destroyed The Old Crypto Growth Metric

BeInCrypto•2026/09/13 22:30